Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court
This article was originally published in The Tan Sheet
Executive Summary
The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophy